Astragaloside IV Treats Parkinson’s Disease by Regulating the Proliferation and Differentiation of NSCs through the SHH–Nurr1 Pathway
Recently, there has been a surge of interest in enhancing the differentiation of neural stem cells (NSCs) and supplementing dopamine neurons as a potential treatment for Parkinson’s disease, the second most prevalent neurodegenerative disorder. Two factors, sonic hedgehog (SHH) and nuclear receptor–...
Saved in:
Main Authors: | Zicong Wu, Jianing Zhang, Han Gao, Wentao Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2024-01-01
|
Series: | Stem Cells International |
Online Access: | http://dx.doi.org/10.1155/2024/2792909 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The gut–kidney axis is regulated by astragaloside IV to inhibit cyclosporine A-induced nephrotoxicity
by: Cong Han, et al.
Published: (2025-01-01) -
Astragaloside IV Inhibits NF-κB Activation and Inflammatory Gene Expression in LPS-Treated Mice
by: Wei-Jian Zhang, et al.
Published: (2015-01-01) -
Astragaloside IV attenuates cadmium induced nephrotoxicity in rats by activating Nrf2
by: Yuchen Li, et al.
Published: (2025-01-01) -
Astragaloside IV inhibits pathological functions of gastric cancer-associated fibroblasts through regulation of the HOXA6/ZBTB12 axis
by: Liu Haibo, et al.
Published: (2023-09-01) -
Astragaloside IV inhibits atherosclerosis caused by ferritin autophagy in a lipid deposition environment by activating Nrf2
by: Dandan Liu, et al.
Published: (2025-03-01)